Time for a Treaty? ReAct Reports on Second Consultation on Global Development & Stewardship Framework to Combat AMR

by MAARTEN VAN DER HEIJDEN, Policy Associate, ReAct – Action on Antibiotic Resistance

Last week, the Second Consultation of Member States and Partners on the Global Development and Stewardship Framework to Combat Antimicrobial Resistance (AMR) took place. Like the last meeting in November 2017, non-state actors were invited to participate in the first of the meeting,

A Week of Promise for Access to Medicines

by ALEX LAWRENCE, Communications Advisor

At the 71st World Health Assembly, the great and the good (and sometimes, not so good) of global health came together on some of the most pressing health challenges we face.

On the agenda, and of particular interest to Health Action International (HAI), were the World Health Organization’s (WHO) General Programme of Work (GPW13),

What Role Can Civil Society Play in the European Regulatory Process?

by ANCEL.LA SANTOS, Senior Policy Advisor

The formal engagement of patients and consumers in the pharmaceutical regulatory process helps ensure that important decisions about medicines take into account the thoughts and views of the people they most affect. The European Medicines Agency (EMA) has a long tradition of this kind of stakeholder involvement.

Open Science for Health: Shaping the New Framework Programme

by JAUME VIDAL, Policy Advisor - Europe Health Action International (HAI) and Commons Network were joined last week in a packed room at the European Parliament by European Union lawmakers, policy-makers and other civil society groups to debate the challenges and opportunities ahead for the medical research and development (R&D) system. Open Science for Health [...]

Staff Spotlight: Tim Reed

A famous man, John Quincy Adams, once said, “If your actions inspire others to dream more, learn more, do more and become more, you are a leader”. Mr Adams was the sixth president of the United States of America—and the first to give an interview to a female journalist, Anne Royall, which was quite progressive for his time.

Giving Snakebite Victims a Voice

Health Action International Presents “Minutes to Die” at the Dutch Global Health Film Festival

by BIRTE BOGATZ, Communications Advisor

How do you measure the burden of a health emergency? We often tend to do that by counting—the dead, the disabled, the dollars to be paid for treatment. We end up with numbers,

HSA4A Signs Partnership Agreement to Address Sexual and Reproductive Health and Rights in East Africa

by THE HSA4A PARTNERSHIP

Maternal mortality is the number one cause of death in sub-Saharan Africa. Despite the fact that maternal mortality is high on the international agenda, the goal to reduce maternal mortality by 75 percent by 2015, is still far from being reached. By advocating and influencing the availability of affordable medicines and contraception and increasing the availability and accessibility of skilled health workers,  

Conference contemplations: ‘Pharmaceuticals and global health – inequalities and innovation in the 21st century’

By LEAH COWAN

On 19 July, over 150 participants from consumer groups, policy and research bodies, universities and NGOs attended the annual Global Health Conference at the University of Sussex: ‘Pharmaceuticals and Global Health – Inequalities and Innovation in the 21st Century’. It was a pleasure to return to one of Britain’s greenest and beautifully-located campuses,

Despite concrete steps forward, the ENVI vote on clinical trials regulation falls short on transparency

By ANCEL.LA SANTOS QUINTANO

On 29 May 2013 the European Parliament’s Environment, Public Health and Food Safety (ENVI) Committee voted unanimously in favour of a draft body of rules governing the authorisation and conduct of clinical trials in the EU. HAI Europe welcomes advancements in this legislative process towards increased access to clinical trial data but notes that more needs to be done.

Study provides recommendations on European Medicines Agency's communication on medicines

A recently published study produced by an independent expert offers recommendations to assist the European Medicines Agency’s communication on the benefits and risks of medicines.

The report is a result of a year long project carried out by Dr Frederic Bouder and aims to provide evidence based input.

The study not only contains a detailed analysis of the expectations and attitudes of the different stakeholders of the agency regarding its communication on medicines but also draws up detailed recommendations for the agency such as the setting up of a risk communication advisory board.

START TYPING AND PRESS ENTER TO SEARCH